Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

12EZ

A.fulgidus RioK1 bound to small molecule KPSH02

This is a non-PDB format compatible entry.
Summary for 12EZ
Entry DOI10.2210/pdb12ez/pdb
DescriptorRIO-type serine/threonine-protein kinase Rio1, 4-amino-7-[5-thio-5-S-(1H-1,2,4-triazol-3-yl)-alpha-L-arabinofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (3 entities in total)
Functional Keywordsrio kinase 1, inhibitor, riok1, transferase
Biological sourceArchaeoglobus fulgidus
Total number of polymer chains2
Total formula weight59788.48
Authors
Hunter, D. (deposition date: 2026-04-01, release date: 2026-08-26, Last modification date: 2026-09-02)
Primary citationHunter, D.A.,Yu, W.,Puranik, P.,Banerjee, A.,Pozharski, E.,Seraj, N.,Chang, M.,Cooper, J.,Strickland, D.,Dave, V.,LaRonde, N.,MacKerell Jr., A.D.,Weber, D.J.
Structure of an inhibitor bound to the catalytically important divalent metal ion site of afRioK1.
J.Struct.Biol., 218:108355-108355, 2026
Cited by
PubMed Abstract: Rio Kinase 1 (RioK1) is an anti-cancer target for colorectal cancer. In pursuit of selective inhibitors of RioK1, small drug-like molecules were identified using computer-aided drug design (CADD). CADD made use of a 3D crystal structure of human RioK1 bound to ADP/Mg and a fragment-based computational method termed Site-Identification by Ligand Competitive Saturation (SILCS). Compounds identified via SILCS were selected based on predicted binding affinities and were experimentally confirmed to bind a RioK1 homolog from Archaeoglobus fulgidus via biophysical methods. One newly designed scaffold molecule, KPSH02, had its X-ray crystal structure determined in complex with afRioK1. The structure confirmed that KPSH02 occupies the adenine binding region seen in the Toyocamycin-afRioK1 structure, while also occupying the divalent metal-ion site observed in the hsRioK1-ADP structure. This structure thereby provides novel insights that may be exploited for the design of selective RioK1 inhibitors that may be useful in the future for targeting RioK1 in cancer.
PubMed: 42595235
DOI: 10.1016/j.jsb.2026.108355
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.76 Å)
Structure validation

259693

PDB entries from 2026-09-16

PDB statisticsPDBj update infoContact PDBjnumon